Table 2.
Response to first-line therapy.
| Characteristics | All patients (n = 366) | Non-ILD (n = 269) | All ILD (n = 97) | p value (versus non-ILD) | IPF (n = 75) | p value (versus non-ILD) | Non-IPF ILD (n = 22) | p value (versus non-ILD) |
|---|---|---|---|---|---|---|---|---|
| First-line therapy | ||||||||
| Chemoradiotherapy (rate in LD) | 121 (73%) | 103 (83%) | 18 (44%) | < 0.0001 | 10 (38%) | < 0.0001 | 8 (53%) | 0.0132 |
| Chemotherapy | 245 | 166 | 79 | 65 | 14 | |||
| First-line chemotherapeutic regimen | ||||||||
| Platinum-doublet | 362 (99%) | 265 (99%) | 96 (99%) | 1.0000 | 75 (100%) | 0.5804 | 21 (95%) | 0.3269 |
| Cisplatin/carboplatin | 131 (36%)/231 (64%) | 113 (42%)/153 (58%) | 18 (19%)/78 (81%) | < 0.0001 | 12 (16%)/63 (84%) | < 0.0001 | 6 (29%)/15 (71%) | 0.2550 |
| Etoposide/irinotecan | 311 (86%)/52 (14%) | 225 (84%)/42 (16%) | 86 (90%)/10 (10%) | 0.2367 | 67 (89%)/8 (11%) | 0.3553 | 19 (90%)/2 (10%) | 0.7516 |
| Others | 4 (1%) | 3 (1%) | 1 (1%) | 0 (0%) | 1 (5%) | |||
| Response to first-line therapy: all/LD/ED stages | ||||||||
| CR | 62/53/9 | 54/45/9 | 8/8/0 | 5/5/0 | 3/3/0 | |||
| PR | 234/97/137 | 173/70/103 | 61/27/34 | 47/17/30 | 14/10/4 | |||
| SD | 26/6/20 | 15/2/13 | 11/4/7 | 10/3/7 | 1/1/0 | |||
| PD | 38/8/30 | 22/6/16 | 16/2/14 | 12/1/11 | 4/1/3 | |||
| NE | 6/1/5 | 5/1/4 | 1/0/1 | 1/0/1 | 0/0/0 | |||
| Response rate | 82/91/74% | 86/93/79% | 72/85/62% | 0.0029/0.1164/0.0170 | 70/85/63% | 0.0029/0.2243/0.0322 | 77/87/57% | 0.3409/0.6280/0.3804 |
| Each chemotherapeutic regimen: CR + PR/SD + PD (response rate) | ||||||||
| Cisplatin + etoposide | 86/10 (90%) | 75/8 (90%) | 11/2 (85%) | 0.6212 | 6/2 (75%) | 0.2124 | 5/0 (100%) | 1.0000 |
| Carboplatin + etoposide | 164/47 (78%) | 115/24 (83%) | 49/23 (68%) | 0.0226 | 39/19 (67%) | 0.0227 | 10/4 (71%) | 0.2888 |
| Cisplatin + irinotecan | 30/3 (91%) | 26/2 (93%) | 4/1 (80%) | 0.3996 | 4/0 (100%) | 1.0000 | 0/1 (0%) | 0.1034 |
| Carboplatin + irinotecan | 10/4 (71%) | 7/3 (70%) | 4/1 (80%) | 1.0000 | 3/1 (75%) | 0.3395 | 1/0 (100%) | 1.0000 |
CR, complete response; ILD, interstitial lung disease; IPF, idiopathic pulmonary fibrosis; LD, limited disease; NE, not evaluable; PD, progressive disease; PR, partial response; SD, stable disease.